THIS IS A SOURCES SOUGHT ANNOUNCEMENT, A MARKET SURVEY FOR

WRITTEN INFORMATION ONLY. THIS IS NOT A SOLICITATION

ANNOUNCEMENT FOR PROPOSALS AND NO CONTRACT WILL BE AWARDED

FROM THIS ANNOUNCEMENT. NO REIMBURSEMENT WILL BE MADE FOR ANY

COSTS ASSOCIATED WITH PROVIDING INFORMATION IN RESPONSE TO THIS

ANNOUNCEMENT OR ANY FOLLOW-UP INFORMATION REQUESTS. NO

TELEPHONE CALLS WILL BE ACCEPTED REQUESTING AN RFQ PACKAGE OR

SOLICITATION. THERE IS NO RFQ PACKAGE OR SOLICITATION. IN ORDER TO

PROTECT THE PROCUREMENT INTEGRITY OF ANY FUTURE PROCUREMENT,

IF ANY, THAT MAY ARISE FROM THIS ANNOUNCEMENT, INFORMATION

REGARDING THE TECHNICAL POINT OF CONTACT WILL NOT BE GIVEN AND

NO APPOINTMENTS FOR PRESENTATIONS WILL BE MADE.

The U.S. Food and Drug Administration (FDA), Office of Acquisitions and Grants Services (OAGS) issues this Sources Sought announcement on behalf of the National Center for Toxicological Research (NCTR) in order to determine if there are existing small business sources capable of providing a Life Technologies Quantstudio 7 Flex Real-Time PCR (qPCR) Service Agreement (“AB Assurance” or equal plan) for instrument serial number 278871548 for a Base Year plus two possible option years.

The instrument is currently under a service agreement which expires on 08/14/2026 so the new service agreement will begin on 08/15/2026.

If your firm is considered a small business source under North American Industry Classification System (NAICS) 811210 – Other Electronic and Precision Equipment Repair and Maintenance; with a Small Business Size Standard of $34 Million, and you believe that your firm would be able to provide the FDA with the products described below, please submit an email to suzanne.martella@fda.hhs.gov.

Other than small business concerns are also encouraged to submit capability statements. The vendor shall include information about the company and demonstrate that it can meet all of the minimum performance requirements.

This Sources Sought is for a Brand Name or Equal solution. Proposed equal needs to meet all the Minimum Performance Requirements listed below to be deemed technically acceptable.

Minimum Performance Requirements for the Preventative Maintenance & Unlimited Repair Service Contract:

1. Shall include all parts, labor and travel necessary to provide preventative maintenance and unlimited corrective repair services on the entire Life Technologies Quantstudio 7 Flex Real-Time PCR (qPCR) (S/N: 278871548)

2. Shall include one (1) Preventative Maintenance inspection per service agreement year on the qPCR and accessory blocks (Fast 96-well, 384-well, and TaqMan Array Cards)

3. Shall include calibration and temperature verification of blocks

4. During a PM service visit, the field service engineer shall perform inspection of the system, software update if required, cleaning, lubricating, and alignment of relevant mechanical parts, mailto:suzanne.martella@fda.hhs.gov cleaning and alignment of optical systems, functional tests and performance verification, documentation of maintenance tasks, results, and findings.

5. Shall include guaranteed priority response time of 2 business days after receipt of a service call.

6. Scheduled and emergency service shall be performed between the hours of 8:00 am and 5:00 pm Monday through Friday, excluding holidays.

7. Shall include priority telephone and email access to instrument technical support.

8. Remote support shall be available.

9. Shall include an Original Equipment Manufacturer (OEM) formally trained and certified technicians/engineers for all maintenance and repair activities performed

10. The maintenance and repair activities shall be performed following the OEM specifications, manuals and service bulletins, using new OEM replacement parts, components, subassemblies, etc.

Deliverables: Service Records and Reports: The Contractor shall, commensurate with the completion of each preventive maintenance service visit, provide the end-user of the equipment with a copy of a field service report/ticket identifying the equipment name, manufacturer, model number, and serial number of the equipment being serviced, a detailed description of the work performed, the test instruments or other equipment used to perform the service, the name(s) and contact information of the technician who performed the service, and for information purposes, the on-site hours expended, and parts/components replaced. In addition, the Contractor shall provide a written report to the FDA COR and Contract Specialist, summarizing all maintenance activities (including warranty work) each time service is performed.

Period(s) of Performance: Base plus two (2) Option Years with the following period of performance dates:

Base Year: 08/15/2026 – 08/14/2027 Option Year 1: 08/15/2027 – 08/14/2028 Option Year 2: 08/15/2028 – 08/14/2029

Place of Performance The service shall be performed at the National Center for Toxicological Research (NCTR) at the following address:

US FDA/NCTR

3900 NCTR Rd

BLDG 53D-209

Jefferson AR 72079

Responses to this Sources Sought shall unequivocally demonstrate that the respondent is regularly providing a Life Technologies Quantstudio 7 Flex Real-Time PCR (qPCR) Service. Though the target audience is small business vendors or small businesses capable of supplying a U.S.

product/service of a small business vendor or producer, all interested parties may respond. At a minimum, responses shall include the following:

• Business name and bio, Unique Entity ID (SAM) number, business address, business website, business size status (i.e., SB, VOSB, SDVOSB, HUBZone SB, SDB, WOSB, LB), point of contact name, mailing address (if different from business address), phone number and email address. Provide this same information again if responding to provide a service offered by another firm.

• Descriptive literature, brochures, marketing material, etc. detailing the preventive-corrective maintenance services which the responding firm is regularly engaged in providing, including services for the Life Technologies Quantstudio 7 Flex Real-Time PCR (qPCR). Capability statements must provide sufficient information that unequivocally demonstrates that the technical requirements and/or delivery time identified above can be met.

• Past Performance (within the last 3 years) information for the sale of same or substantially similar product/service to include date of sale, description, dollar value, client name, client address, client contact name, client point of contact mailing address (if different from that provided for client), client point of contact phone number, client point of contact email address, and name of the manufacturer (to include Unique Entity ID (SAM) number and size status) if not the respondent.

• The offeror shall furnish sufficient technical information necessary for the Government to conclusively determine that the offered products/services meet the technical requirements identified above.

• The offeror’s estimated historical on-site response time for the brand name and model of instrument in this requirement.

• The offeror’s capability to initiate service within the two-day response-time requirement from original notification.

• If applicable, identification of the firm’s GSA Schedule contract(s) by Schedule number and SINs that are applicable to this potential requirement are also requested.

• If applicable, identification of Best in Class (BIC) contract information or other Government-wide or HHS-wide contracts that the equipment/service is available on.

• If a large business, provide whether subcontracting opportunities exist for small business concerns.

• Standard commercial warranty and payment terms.

• Provide place of product manufacture or service performance and any other applicable information to enable review and analysis pertaining to the Buy American statute and requirements relating to Made in America in the event a nonavailability waiver request through the MIAO Digital Waiver Portal is needed.

• Though this is not a request for quote, informational pricing for the products would be helpful for market research purposes.

The Government is not responsible for locating or securing any information not identified in the response.

Interested Contractors must respond with capability statements which are to be submitted by email only to the point of contact listed below on or before 2:00 pm (Central Time in Jefferson AR) on May 18, 2026 to Suzanne Martella, email suzanne.martella@fda.hhs.gov. Reference:

75F40126SSN132996.

Disclaimer and Important Notes

This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work.

Responses with weblinks will not be opened or viewed.

Responses must demonstrate capability, not merely affirm the respondent’s capability (i.e. the response must go beyond the statement that, “XYZ company can provide the instrument, technical support etc.”).

Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted.

After a review of the responses received, a pre‐solicitation synopsis or combined synopsis/ solicitation may be published in SAM.gov – Contracting Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation.

Confidentiality and Proprietary Information

No proprietary, classified, confidential, or sensitive information should be included in your response.

The Government reserves the right to use any non‐proprietary technical information in any resultant solicitation(s).

Additional Notes:

If the stated requirements appear restrictive, please submit comments detailing the concern. Though this is not a request for quote, informational pricing for the service would be helpful.

mailto:suzanne.martella@fda.hhs.gov